parallel trade and the pricing of pharmaceutical products frank müller-langer conference on...
TRANSCRIPT
![Page 1: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/1.jpg)
Parallel Trade and the Pricing of Pharmaceutical Products
Frank Müller-Langer
Conference on„Health Economics and the Pharmaceutical
Industry“
![Page 2: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/2.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
2
Agenda
1 Introduction
2 Prior literature
3 Double marginalization model with complete information
4 Conclusion and ideas for further research
![Page 3: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/3.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
3
Parallel imports (PIs)
• When do parallel imports actually occur?• Why should we care about parallel imports?
- Advocates of strong patent rights for new pharmaceutical products support a global regime of banning parallel imports- Restraints on parallel imports vary widely between developed and developing countries and even amongst developed countries
![Page 4: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/4.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
4
Questions to be analyzed
1. Why may parallel imports actually occur in equilibrium when information is complete?
2. Are parallel imports beneficial or detrimental to the producer of a patented product?
![Page 5: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/5.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
5
Agenda
1 Introduction
2 Prior literature: Determinants of parallel trade
3 Double marginalization model with complete information
4 Conclusion and ideas for further research
![Page 6: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/6.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
6
Determinants of Parallel Trade
First strand of literatureExclusive distribution rights in foreign markets, vertical price control and parallel trade [Maskus and Chen (2002, 2004)]
![Page 7: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/7.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
7
Determinants of Parallel Trade
Second strand of literaturePrice regulations by national governments and parallel trade [Ganslandt and Maskus (2004), Jelovac and Bordoy (2005)]
![Page 8: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/8.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
8
Agenda
1 Introduction
2 Prior literature
3 Double marginalization model with complete information
4 Conclusion and ideas for further research
![Page 9: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/9.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
9
Double Marginalization Game: Assumptions
• Player 1: Monopolistic manufacturer of pharmaceuticals in country A
• Manufacturer has marginal costs of zero• Player 2: Exclusive distributor in country B• Players’ payoff functions: their profits• Demand in country A:• Demand in country B:• Parallel imports are allowed (perfect substitute)• Distributor: marginal costs of parallel trade,
with 1A A AD ( p ) a bp
B B BD ( p ) a bp
wBp t
![Page 10: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/10.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
10
Structure of the game
• First stage: manufacturer chooses the wholesale price at which he sells the pharmaceutical product to the distributor in country B,
• Second stage: distributor chooses the retail price in country B, pB
• Third stage: manufacturer and distributor simultaneously choose the prices at which they sell the product in country A in a Bertrand price competition, and .
wBp
mAp d
Ap
![Page 11: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/11.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
11
Bertrand price competition
• Rules of the gameThe low-price firm serves the entire market
The high-price firm sells nothing• Manufacturer has marginal costs of zero• Distributor has positive marginal costs of
• Manufacturer sets a price that is smaller than the marginal costs of the distributor,
wBp t
m wA Bp t p
![Page 12: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/12.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
12
Bertrand price competition
Result: PIs will never occur in any sub-game perfect Nash equilibrium in the double marginalization game with complete information
![Page 13: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/13.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
13
Distributor‘s decision
• In the second stage, the distributor anticipates that he will be driven out of the market in country A in the third stage
• In the second stage, the distributor sets a retail price in country B that is 50 per cent higher than the wholesale price set by the manufacturer
![Page 14: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/14.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
14
Maximization problem of the manufacturer
subject to 0
and 0
and
m wA B
wm m w BA A B
p ,p
mA
wB
m wA B
a-bpmax p a bp +p
2
p
p
p t p
![Page 15: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/15.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
15
Solution 1 for low trade costs and high
• We use the Kuhn-Tucker Theorem and obtain two solutions
• Solution 1:
• Solution 1 only satisfies the non-negativity restrictions if
12 1
6 3m*A
ap t
b
12
at
b
22 1
6 3w*B
ap t
b
![Page 16: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/16.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
16
Solution 2 for
• equal to the monopoly price in the double marginalization game when parallel imports are prohibited
• equal to the profit-maximizing wholesale price in the double marginalization game when parallel imports are prohibited
12
a
tb
2m**A
ap
b
2w**B
ap
b
![Page 17: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/17.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
17
Equilibrium Quantities and Prices
PI‘s allowed PI‘s prohibited
Price in A
Quantity in A
Wholesale Price in B
Retail Pr. in B
Quantity in B
2m**A
ap
b
2w**B
ap
b
3 6 3m*A
a a tp
b b
2
3 6 3w*B
a a tp
b b
2**A
aq
2
3 6 3*A
a a btq
4**B
aq 5
12 6 3*B
a a btq
3
4**B
ap
b
7
12 6 3*B
a a tp
b b
![Page 18: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/18.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
18
Profit of the manufacturer
1. Parallel imports are allowed:
2. Parallel imports are prohibited:
* m* * w* *A A B Bp q p q
2 2 2 2 2
24 3 3 6 3 6* a at bt a at a
b b b
** m** ** w** **A A B Bp q p q
2 2 2
8 4** a a
b b
![Page 19: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/19.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
19
Net effect on profit when PI‘s are allowed
and
and as b >0.
* ** 2 2 2 2 2
12 3 3 6 3 12
a at bt a at a
b b b
20 1
3 3 3 2maxa bt a a
tt b
2
2
20
3
b
t
![Page 20: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/20.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
20
Net effect on profit when PI‘s are allowed
• For we obtain:
• Hence,
• Result: Manufacturer generates a lower profit when parallel imports are allowed
0
0 maxt \ t
maxt
![Page 21: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/21.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
21
Results of the welfare analysis
• The net effect of parallel trade on global welfare is positive if the market in country A is large ( )
• The net effect of parallel trade on global welfare can be negative if trade costs are at an intermediate level and countries are virtually homogenous in terms of market size ( )
5 2/
1
![Page 22: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/22.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
22
Summary of the main results
• PIs will never occur in a double marginalization game with complete information
• If , potential competition from parallel trade does not arise. The manufacturer charges the monopoly price in country A and the optimal wholesale price in country B
• If , potential competition from parallel trade arises. The manufacturer strategically sets the wholesale price in country B and the price in country A, in order to prevent that parallel trade occurs
12
at
b
12
at
b
![Page 23: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/23.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
23
Summary of the main results
• The manufacturer generates a lower profit when parallel imports are allowed as he has to set prices strategically in order to deter parallel imports
![Page 24: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/24.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
24
Agenda
1 Introduction
2 Prior literature
3 Double marginalization model with complete information
4 Ideas for further research
![Page 25: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/25.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
25
Ideas for further research
• Does parallel trade occur when country A is less attractive in terms of market size, [ ], and trade costs are very low [ ] ?
• Impact of a price cap in country B?
0 0t
![Page 26: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/26.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
26
Ideas for further research
• Parallel trade and medicines for neglected infectious and tropical diseases- 99 per cent of global demand for medicines for such diseases is generated in the developing world- Country A high-income country:
- Country B low-income country:
with 1A A AD ( p ) a bp
with 1B B BD ( p ) a bp
![Page 27: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/27.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
27
Thank you
![Page 28: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/28.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
28
Follow-up paper: New timing of the game
• Stage 0: Manufacturer chooses retail price in country A
• Stage 1: Manufactuer chooses wholesale price in country B
• Stage 2: Distributor chooses retail price in country B
• Stage 3: If , a third firm will enter the market, buys the product from the distributor in country B and then re-sells the product in country A
m wA B p t p
![Page 29: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/29.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
29
Game with asymmetric information
• First stage: Manufacturer chooses the price at which he charges the distributor in country B
• Second stage: Nature chooses the demand in country A and country B
• Third stage: Distributor chooses the price he charges his customers in country B
• Fourth stage: Manufacturer and distributor play a Bertrand game
![Page 30: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/30.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
30
Hypothesis
Depending on Nature’s choices with regard to local demand functions parallel imports may occur in equilibrium
![Page 31: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/31.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
31
Social welfare analysis of parallel imports
• Infectious diseases kill 14 million people around the world every year, with 90 per cent of those deaths occurring in the developing world
• Furthermore, almost 1,400 new medicines have been developed in the last 25 years, but only 1 per cent of these were medicines for parasitic and infectious tropical diseases that are rampant in the developing world
![Page 32: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/32.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
32
Hypothesis
• Hypothesis: There is an important rationale for restricting parallel importation of medicines for parasitic and infectious tropical diseases that are rampant in middle income and low income countries
• Parallel imports would further reduce the incentives to invest in R&D for medicines for parasitic and infectious tropical diseases
![Page 33: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/33.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
33
Parallel Imports and the WTO
• WTO members are free to choose whether to allow or prohibit parallel imports
• Article 6 of the TRIPS Agreement:“For the purposes of dispute settlement under this Agreement, subject to the provisions of Articles 3 and 4, nothing in this Agreement shall be used to address the issue of the exhaustion of intellectual property rights.”
![Page 34: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/34.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
34
Distributor‘s decision
• In the second stage, the distributor anticipates that he will be driven out of the market in country A in the third stage
• Parallel trade does not occur
• Total profit is equal to the profit generated in country B through exclusive distribution
![Page 35: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/35.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
35
Distributor‘s decision
• The distributor has to pay the wholesale price
• Maximizes profit according to:
wBp
B
wB B B
pmax p p a bp
![Page 36: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/36.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
36
Distributor‘s decision
• The first-order condition is given by:
2 0wB B
B
a bp bpp
2
ww B
B B
a bpp ( p )
b
![Page 37: Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“](https://reader035.vdocuments.us/reader035/viewer/2022062518/56649f095503460f94c1debd/html5/thumbnails/37.jpg)
Frank Müller-LangerUniversity of HamburgInstitute of Law and Economics
37
Parallel trade can have a negative effect on global welfare [ , and ] 100a 1 2b / 13 8/